Laurus Labs
- Market cap
- ₹ 1,06,658 Cr.
- P/E
- 97.3x
- P/B
- 20.4x
- 52-week range
- 917.95 – 2,143.1
- ROE
- 18%
- ROCE
- 18%
- Dividend yield
- 0.1%
- Debt / equity
- 0.48
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Laurus Labs Limited is an India-based company. The Company is a pharmaceutical manufacturing organization. It is engaged in developing and manufacturing active pharmaceutical ingredients (APIs) and intermediates. It supplies anti-retroviral APIs and intermediates. It provides contract and custom manufacturing solutions, allowing client organizations to outsource various stages of the manufacturing process. It is also engaged in development and manufacturing of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements catering to the needs of stem cells and regenerative medicine, vaccines and biological drugs, cultured meat, and cell-culture media manufacturing. It offers precision fermentation as a contract development and manufacturing organization (CDMO) service. Its service is offered to protein companies and bio-manufacturers operating across healthcare, food, nutrition, personal care, and bio-based materials markets.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Laurus Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)97.3 against a typical 33.2: pricier than most peers (1st = cheapest).193rd of 220
- Sales growth+29% against a typical +15.6% from a year earlier.59th of 197
- Profit growth+123.5% against a typical +18.9% from a year earlier.25th of 160
- Share price, 3 months+20.2% against a typical −1.8%.31st of 200
- Size₹ 1,06,657.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).5th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE AA | Stable | 3 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 3 Jul 2026 | Reaffirmed | CARE AA | — | CARE | ₹ 4,440.53 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2026 and dividend |
| 24 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 30 Apr 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 23 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 23 Oct 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2025 and dividend |
| 25 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 24 Apr 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| Expenses | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 |
| Operating Profit | 188 | 181 | 241 | 171 | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 |
| OPM % | 15% | 15% | 17% | 14% | 15% | 20% | 24% | 24% | 24% | 27% | 28% | 32% |
| Other Income | 2 | 2 | 19 | 3 | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 |
| Interest | 42 | 51 | 50 | 49 | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 |
| Depreciation | 93 | 98 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 |
| Profit before tax | 54 | 35 | 107 | 18 | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 |
| Tax % | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% |
| Net Profit | 37 | 23 | 75 | 13 | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 |
| EPS in Rs | 0.69 | 0.43 | 1.4 | 0.23 | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.66 | 5.17 | 6.8 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 14%
- 5 Years
- 7%
- 3 Years
- 4%
- TTM
- 23%
- 10 Years
- 21%
- 5 Years
- −2%
- 3 Years
- 4%
- TTM
- 115%
- 10 Years
- —
- 5 Years
- 22%
- 3 Years
- 67%
- TTM
- —
- 10 Years
- 17%
- 5 Years
- 15%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Laurus Labs | ₹ 2,181.90 | ₹ 1,06,658 Cr. | 97.3x | 20.4x | 18% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Satyanarayana Chava
- Chief Executive Officer, Executive Director
- Venkata Vantaram Ravi Kumar
- Chief Financial Officer, Executive Director
- V. Uma Maheswer Rao
- President - Chemical R&D
- Srinivasa Rao Suryadevara
- President - Manufacturing and Operations
- Thomas Versosky
- President - FDF, North America
- Sita Ramaiah
- Executive Vice President - Finance
- Narasimha Rao Chava
- Executive Vice President - Human Resources
- Jyothi Basu Abbibeni
- Executive Vice President - Chemical R&D
Prices are delayed and for information only. Nothing on this page is investment advice.